Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Steven Gannon Biography and Net Worth

Director of Xenon Pharmaceuticals

Mr. Gannon has served as a member of our Board since May 2015. Mr. Gannon has served as chairman of the board of directors of Altasciences, a private CRO/CDMO company, since April 2021; on the board of directors of Fusion Pharmaceuticals, a public biopharmaceutical company, since January 2020; on the board of directors of Ritedose Pharmaceuticals since March 2022; and on the board of Laborie Technologies since September 2016. Mr. Gannon also served on the board of directors of enGene Inc., a biotechnology company, from February 2017 to June 2023, and on the board of directors of Aerogen Limited, a medical technology company, from November 2018 to July 2020. From June 2014 to March 2018, Mr. Gannon served on the board of directors of Advanced Accelerator Applications SA, a healthcare company acquired by Novartis in January 2018. Mr. Gannon was Chief Financial Officer, Senior Vice President of Finance and Treasurer at Aptalis Pharma Inc. until February 2014, after which it was sold to Forest Laboratories. Prior to joining Aptalis in 2006, Mr. Gannon served as the Chief Financial Officer for Cryocath Technologies Inc. from 1999 to 2006, as the Director of Finance and Administration of the Research Division of AstraZeneca Canada Inc. from 1996 to 1999, and as the Chief Financial Officer of Mallinckrodt Medical Inc.’s Canadian operations from 1989 to 1995. He received a bachelor of commerce in accounting and business systems from Concordia University in Montreal, Canada in 1983, and completed the Executive Program at the Richard Ivey School of Business at the University of Western Ontario in Ontario, Canada in 1995. He has been a CPA, CA since 1985.

What is Steven Gannon's net worth?: The estimated net worth of Steven Gannon is at least $77,260.00 as of March 7th, 2024. Mr. Gannon owns 2,000 shares of Xenon Pharmaceuticals stock worth more than $77,260 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Gannon may own. Learn More about Steven Gannon's net worth.
How do I contact Steven Gannon?: The corporate mailing address for Mr. Gannon and other Xenon Pharmaceuticals executives is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. Xenon Pharmaceuticals can also be reached via phone at (604) 484-3300 and via email at [email protected]. Learn More on Steven Gannon's contact information.
Has Steven Gannon been buying or selling shares of Xenon Pharmaceuticals?: Steven Gannon has not been actively trading shares of Xenon Pharmaceuticals during the last quarter. Most recently, Steven Gannon sold 13,000 shares of the business's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $46.28, for a transaction totalling $601,640.00. Following the completion of the sale, the director now directly owns 2,000 shares of the company's stock, valued at $92,560. Learn More on Steven Gannon's trading history.
Who are Xenon Pharmaceuticals' active insiders?: Xenon Pharmaceuticals' insider roster includes James Empfield (EVP), Steven Gannon (Director), Frank Holler (Director), Christopher Kenney (Insider), Ian Mortimer (President and Chief Executive Officer), Gary Patou (Director), Simon Pimstone (Director), Robin Sherrington (EVP), Dawn Svoronos (Director), and Christopher Von Seggern (Insider). Learn More on Xenon Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Xenon Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 43,737 shares worth more than $1,903,860.53. The most recent insider tranaction occured on December, 18th when CFO Sherry Aulin sold 18,709 shares worth more than $770,997.89. Insiders at Xenon Pharmaceuticals own 5.5% of the company. Learn More about insider trades at Xenon Pharmaceuticals.
Information on this page was last updated on 12/18/2024.

Steven Gannon Insider Trading History at Xenon Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/7/2024	Sell	13,000	$46.28	$601,640.00	2,000
8/11/2017	Buy	15,000	$2.82	$42,300.00	15,000

Steven Gannon Buying and Selling Activity at Xenon Pharmaceuticals

Xenon Pharmaceuticals Company Overview

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Today's Range

Now: $38.63

$38.00

$39.46

50 Day Range

MA: $41.85

$38.31

$45.74

2 Week Range

Now: $38.63

$35.53

$50.99

Volume

1,054,236 shs

Average Volume

391,447 shs

Market Capitalization

$2.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19